C Diff Drug Development

SER-109, an investigational oral microbiome therapeutic, was well-tolerated and durably reduced rates of recurrent Clostridioides difficile infection through 24 weeks, with benefits showing as early as week 2, data show. SER-109 (Seres Therapeutics) is an oral capsule prepared from healthy donor stool containing dormant Firmicute spores that are activated in the lower GI tract. It received orphan

Clostridioides difficile Infection (CDI) is a bacterial infection of  the large intestine (colon).  A spectrum of clinical disease ranges from...

NTCD-M3 for Clostridioides difficile Infections (CDI) Professor Mark Wilcox presents at the Destiny Pharma R&D Investor Update meeting – 18th October 2022 Professor Dale Gerding discusses the threat of C. difficile infections NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. It is an

.@VedantaBio is a biopharma company pioneering the development of defined bacterial consortia as oral therapies to modulate the #microbiome to treat disease. Its pipeline includes product candidates for #CDiff, #IBD, Gram-negative infections & tumors. https://t.co/zhKTMiqZ73— MTIG (@MTIG_News) November 11, 2022

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market...

A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su …

Fruits such as apples are a dietary source of polyphenols and have health benefits. We studied the benefits of apple polyphenols in reducing intestinal infections. We explored the potential roles of apple polyphenols in combating Clostridioides difficile-induced intestinal infections by modul …

MICROBIOME MEDICINE - Imperial is partnering with biotechnology company EnteroBiotix on research into the potential of therapies based on the gut bacterial community.

A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su …

Follow-up of SER-109 for recurrent C. difficile

Both sporicidal and virucidal standards EN14476 and EN17126 were met or exceeded

Our R&D pipeline includes several programs that address areas of significant unmet medical needs including C. diff infection, MRSA, tuberculosis, and more.

Building on the success seen with fecal microbiota transplantation, this experimental treatment lowered the rates of recurrent C difficile infections.

After 6 months following treatment, 90.5% (38 of 42) responders to RBX2660 remained recurrence-free, whereas 85% (17 of 20) patients in the placebo group remained recurrence-free.

NCT03244644; 9 August, 2017.

Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence ...

CHARLOTTE, N.C. — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, highlighted how live microbiota-based products, such as RBX2660, could drastically transform the treatment of recurrent C. difficile infection.“One of the biggest challenges associated with C. difficile infection is recurrence,” Feuerstadt, assistant clinical professor of medicine at the Yale

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

Clostridium Difficile Infections pipeline constitutes 25+ key companies continuously working towards developing 25+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Clostridium Difficile Infections Overview Clostridium Difficile Infections, also known as Clostridioides difficile or C. difficile is a type of bacteria that causes […]

RBX2660 reduced clostridioides difficile infection recurrence at 8 weeks, with a sustained clinical response through 6 months, in an open-label phase 3 cohort of patients representative of real-world clinical practice.

Antibiotics followed by oral SER-109 demonstrated a low rate of recurrent clostridioides difficile infection through week 8, regardless of the number of prior episodes.

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.

#idweek2022 #idtwitter clinical trials in bacterial dz that may change your practice @julie_justo #CDI #FMT #microbiota #idmeded #meded pic.twitter.com/Ok8xExcivY— Saira Butt (@SAIRABT) October 23, 2022

@Khanna_S summarizing bezlotoxumab and #FMT pic.twitter.com/KwypHDwF1w— John Damianos, M.D. (@john_damianosMD) October 23, 2022

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,